FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060832805> ?p ?o ?g. }

• W2060832805 endingPage "710" @default.
• W2060832805 startingPage "698" @default.
• W2060832805 abstract "BackgroundMany patients with type 2 diabetes mellitus (T2DM) also have hypertension, which is commonly treated with thiazide diuretics, including hydrochlorothiazide (HCTZ). Canagliflozin, a sodium glucose cotransporter 2 inhibitor developed for the treatment of T2DM, lowers plasma glucose by inhibiting renal glucose reabsorption, thereby increasing urinary glucose excretion and mild osmotic diuresis. Because patients with T2DM are likely to receive concurrent canagliflozin and HCTZ, potential interactions were evaluated.ObjectiveThis study evaluated the effects of HCTZ on the pharmacokinetic and pharmacodynamic properties and tolerability of canagliflozin in healthy participants.MethodsThis Phase I, single-center, open-label, fixed-sequence, 2-period study was conducted in healthy participants. During period 1, participants received canagliflozin 300 mg once daily for 7 days, followed by a 14-day washout period. During period 2, participants received HCTZ 25 mg once daily for 28 days, followed by canagliflozin 300 mg + HCTZ 25 mg once daily for 7 days. Blood samples were taken before and several times after administration on day 7 of period 1 and on days 28 and 35 of period 2 for canagliflozin and HCTZ pharmacokinetic analyses using LC-MS/MS. Blood and urine samples were collected for up to 24 hours after canagliflozin administration on day 1 of period 1 and day 35 of period 2 for pharmacodynamic glucose assessment. Tolerability was also evaluated.ResultsThirty participants were enrolled (16 men, 14 women; all white; mean age, 43.7 years). Canagliflozin AUC during a dosing interval (T) at steady state (AUCτ,ss) and Cmax at steady state (Cmax,ss) were increased when canagliflozin was coadministered with HCTZ, with geometric mean ratios (90% CI) of 1.12 (1.08–1.17) and 1.15 (1.06–1.25), respectively. AUCτ,ss and Cmax,ss for HCTZ were similar with and without canagliflozin coadministration. The 24-hour mean renal threshold for glucose and mean plasma glucose were comparable for canagliflozin alone and coadministered with HCTZ. The change in 24-hour urine volume from baseline was −0.1 L with canagliflozin alone and 0.4 L with HCTZ alone and with canagliflozin + HCTZ. The overall incidence of adverse events (AEs) was higher with canagliflozin + HCTZ (69%) than with canagliflozin (47%) or HCTZ (50%) alone; most AEs were of mild severity. Overall, minimal changes in serum electrolytes (eg, sodium, potassium) were observed after coadministration of canagliflozin + HCTZ compared with individual treatments.ConclusionsAdding canagliflozin treatment to healthy participants on HCTZ treatment had no notable pharmacokinetic or pharmacodynamic effects; canagliflozin coadministered with HCTZ was generally well tolerated, with no unexpected tolerability concerns. ClinicalTrials.gov identifier: NCT01294631." @default.
• W2060832805 created "2016-06-24" @default.
• W2060832805 creator A5022867432 @default.
• W2060832805 creator A5027581435 @default.
• W2060832805 creator A5034243739 @default.
• W2060832805 creator A5047898874 @default.
• W2060832805 creator A5083478319 @default.
• W2060832805 date "2014-05-01" @default.
• W2060832805 modified "2023-10-07" @default.
• W2060832805 title "Effects of Hydrochlorothiazide on the Pharmacokinetics, Pharmacodynamics, and Tolerability of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Healthy Participants" @default.
• W2060832805 cites W1550111394 @default.
• W2060832805 cites W1606165384 @default.
• W2060832805 cites W1962067490 @default.
• W2060832805 cites W1968145432 @default.
• W2060832805 cites W1985567618 @default.
• W2060832805 cites W1997018189 @default.
• W2060832805 cites W2023817623 @default.
• W2060832805 cites W2038270027 @default.
• W2060832805 cites W2046877602 @default.
• W2060832805 cites W2060481079 @default.
• W2060832805 cites W2062686485 @default.
• W2060832805 cites W2068171948 @default.
• W2060832805 cites W2074989651 @default.
• W2060832805 cites W2077038286 @default.
• W2060832805 cites W2078888669 @default.
• W2060832805 cites W2084511068 @default.
• W2060832805 cites W2090088543 @default.
• W2060832805 cites W2105660444 @default.
• W2060832805 cites W2107999700 @default.
• W2060832805 cites W2118613762 @default.
• W2060832805 cites W2120919346 @default.
• W2060832805 cites W2124234371 @default.
• W2060832805 cites W2130570549 @default.
• W2060832805 cites W2135097670 @default.
• W2060832805 cites W2146105386 @default.
• W2060832805 cites W2152397610 @default.
• W2060832805 cites W2167984652 @default.
• W2060832805 cites W2168926920 @default.
• W2060832805 cites W2172193326 @default.
• W2060832805 cites W4230306155 @default.
• W2060832805 doi "https://doi.org/10.1016/j.clinthera.2014.02.022" @default.
• W2060832805 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24726680" @default.
• W2060832805 hasPublicationYear "2014" @default.
• W2060832805 type Work @default.
• W2060832805 sameAs 2060832805 @default.
• W2060832805 citedByCount "45" @default.
• W2060832805 countsByYear W20608328052014 @default.
• W2060832805 countsByYear W20608328052015 @default.
• W2060832805 countsByYear W20608328052016 @default.
• W2060832805 countsByYear W20608328052017 @default.
• W2060832805 countsByYear W20608328052018 @default.
• W2060832805 countsByYear W20608328052019 @default.
• W2060832805 countsByYear W20608328052020 @default.
• W2060832805 countsByYear W20608328052021 @default.
• W2060832805 countsByYear W20608328052022 @default.
• W2060832805 countsByYear W20608328052023 @default.
• W2060832805 crossrefType "journal-article" @default.
• W2060832805 hasAuthorship W2060832805A5022867432 @default.
• W2060832805 hasAuthorship W2060832805A5027581435 @default.
• W2060832805 hasAuthorship W2060832805A5034243739 @default.
• W2060832805 hasAuthorship W2060832805A5047898874 @default.
• W2060832805 hasAuthorship W2060832805A5083478319 @default.
• W2060832805 hasBestOaLocation W20608328051 @default.
• W2060832805 hasConcept C111113717 @default.
• W2060832805 hasConcept C112705442 @default.
• W2060832805 hasConcept C126322002 @default.
• W2060832805 hasConcept C134018914 @default.
• W2060832805 hasConcept C197934379 @default.
• W2060832805 hasConcept C22979827 @default.
• W2060832805 hasConcept C2777180221 @default.
• W2060832805 hasConcept C2777288759 @default.
• W2060832805 hasConcept C2777451236 @default.
• W2060832805 hasConcept C2778375690 @default.
• W2060832805 hasConcept C2780361556 @default.
• W2060832805 hasConcept C555293320 @default.
• W2060832805 hasConcept C71924100 @default.
• W2060832805 hasConcept C84393581 @default.
• W2060832805 hasConcept C98274493 @default.
• W2060832805 hasConceptScore W2060832805C111113717 @default.
• W2060832805 hasConceptScore W2060832805C112705442 @default.
• W2060832805 hasConceptScore W2060832805C126322002 @default.
• W2060832805 hasConceptScore W2060832805C134018914 @default.
• W2060832805 hasConceptScore W2060832805C197934379 @default.
• W2060832805 hasConceptScore W2060832805C22979827 @default.
• W2060832805 hasConceptScore W2060832805C2777180221 @default.
• W2060832805 hasConceptScore W2060832805C2777288759 @default.
• W2060832805 hasConceptScore W2060832805C2777451236 @default.
• W2060832805 hasConceptScore W2060832805C2778375690 @default.
• W2060832805 hasConceptScore W2060832805C2780361556 @default.
• W2060832805 hasConceptScore W2060832805C555293320 @default.
• W2060832805 hasConceptScore W2060832805C71924100 @default.
• W2060832805 hasConceptScore W2060832805C84393581 @default.
• W2060832805 hasConceptScore W2060832805C98274493 @default.
• W2060832805 hasIssue "5" @default.
• W2060832805 hasLocation W20608328051 @default.
• W2060832805 hasLocation W20608328052 @default.
• W2060832805 hasOpenAccess W2060832805 @default.
• W2060832805 hasPrimaryLocation W20608328051 @default.

• next